Implantation response following clinical heart-lung transplantation.
Implantation response has been a critical problem following heart-lung and lung transplantation. While the precise etiology of this problem remains unclear, improvements in organ preservation would be expected to have a beneficial effect on implantation response. The time-related profile of the implantation response was studied in 20 patients who underwent heart-lung transplantation between March 1984-March 1987. In 10 operations the donors had intravenous prostaglandin E-1 pretreatment while 10 had no vasodilatation before explantation of the organs. Otherwise lung preservation and early (2 weeks) immunotherapy were similar in both groups. The implantation response was evaluated by chest films and postoperative lung functions and mechanics. Roentgenographic implantation response was evident from the first postoperative day, was less evident at the seventh postoperative day and then gradually increased during the second postoperative week. There was a tendency towards less implantation response in the PGE-1 group than in the control group, but no statistical difference was observed. Patients with severe operative bleeding problems were excluded from the study. Only peak inspiratory pressures were significantly higher in the control group than in the PGE-1 group (p less than 0.01). Other lung function studies (alveolar-capillary pO2 difference, extubation time) were not different in the groups. This study supported the hypothesis that prostaglandin E-1 may have salutary effects on graft preservation and implantation response in heart-lung transplantation. Since 1986, we have performed 16 heart-lung transplantations using graft preservation with PGE-1 and flush perfusion. Thirty-day mortality is 0% and 13 of 16 patients are surviving.
Harjula
A L
AL
Department of Cardiovascular Surgery, Stanford University Central Hospital, CA.
Baldwin
J C
JC
Silverman
N E
NE
Blank
N
N
Oyer
P E
PE
Stinson
E B
EB
Shumway
N E
NE
D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage; D005260:Female; D016041:Heart-Lung Transplantation / Q000401:mortality / Q000502:physiology; D006801:Humans; D008297:Male; D009926:Organ Preservation; D011183:Postoperative Complications / Q000517:prevention & control; D013902:Radiography, Thoracic; D012129:Respiratory Function Tests; D013997:Time Factors
D000527:Alprostadil